8-K: PDS Biotech Announces Positive Data Update from VERSATILE-002 Trial, Median Overall Survival Reaches 30 Months

PDS Biotechnology reported a median overall survival of 30 months in its VERSATILE-002 Phase 2 clinical trial for head and neck cancer, with many patients approaching three years of follow-up.

Summary

• PDS Biotechnology has provided an update on its VERSATILE-002 Phase 2 clinical trial, which is evaluating the combination of Versamune HPV and pembrolizumab in patients with HPV16-positive head and neck squamous cell cancer.
• The median overall survival (mOS) for immune checkpoint inhibitor (ICI) naive patients remains at 30 months, based on a data cut from May 17, 2024, which includes approximately six months of additional follow-up.
• This mOS is consistent with data presented earlier in May 2024, which was based on a data cut from November 30, 2023.
• The lower limit of the 95% confidence interval for mOS is 19.7 months, and the upper limit is not yet estimable.
• The company plans to initiate a pivotal clinical trial in 2024 for its lead program in advanced head and neck squamous cell cancers.
• The planned trial will have two active arms: a double combination of Versamune HPV and pembrolizumab, and a triple combination of Versamune HPV, PDS01ADC, and pembrolizumab.
• Full data from the May 17, 2024 data cut are expected to be announced in Q3 2024.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, particularly the 30-month median overall survival, which is a significant improvement over existing treatments. The planned pivotal trial and the potential for a new standard of care are also positive. However, the company's financial situation and dependence on future funding are a concern, which prevents a perfect score.

Positives

• The 30-month median overall survival is a significant improvement compared to the less than 18 months survival rate under current standards of care for recurrent and/or metastatic HNSCC.
• The combination of Versamune HPV and pembrolizumab shows a favorable tolerability profile.
• The company has a dual platform approach that targets the tumor from both the inside and outside.
• Oncologists have rated the triple combination therapy highly for use in first-line recurrent/metastatic HNSCC.
• The triple combination has shown a 75% objective response rate in a Phase 2 trial.
• The company has a cash runway into Q4 2025, excluding the costs of the planned pivotal trial.

Negatives

• The company's 10-K for the year ended 12/31/2023 includes a going concern opinion.
• The company is dependent on additional financing to fund its operations and complete the development and commercialization of its product candidates.
• There is a risk that raising additional capital may restrict the company's operations or require the company to relinquish rights to its technologies or product candidates.
• The company has a limited operating history in its current line of business, which makes it difficult to evaluate its prospects.

Risks

• The company's ability to protect its intellectual property rights is a risk.
• The company's anticipated capital requirements and cash runway are subject to change.
• The timing and success of planned clinical trials are uncertain.
• The company's interpretation of clinical trial results may not be sufficient to support the future success of its product candidates.
• The company's ability to continue as a going concern is a risk.
• Legislative, regulatory, political, and economic developments not within the company's control could impact results.

Future Outlook

The company plans to initiate a pivotal clinical trial in 2024 for its lead program in advanced head and neck squamous cell cancers, with two active arms: a double combination of Versamune HPV and pembrolizumab, and a triple combination of Versamune HPV, PDS01ADC, and pembrolizumab. The company also anticipates several milestones in 2024, including regulatory confirmation of the pivotal study, filing an IND for a new study, and providing a clinical update on another trial.

Management Comments

• Dr. Kirk Shepard, M.D., Chief Medical Officer of PDS Biotech stated, 'In recurrent and/or metastatic HNSCC objective response rate and progression-free survival have generally not translated into increased survival, and under current standards of care survival rates are well established to be less than 18 months.'
• Dr. Shepard also stated, 'We believe that our VERSATILE-002 clinical trial and triple combination trial provide us with the critical survival information needed to effectively design the statistical primary endpoint in our planned Phase 3 trial.'

Industry Context

The announcement is significant in the context of head and neck cancer treatment, where current standards of care often result in survival rates of less than 18 months. PDS Biotech's results, showing a median overall survival of 30 months, suggest a potential improvement in patient outcomes. The company's dual platform approach and triple combination therapy are also notable in the broader immuno-oncology landscape.

Comparison to Industry Standards

• The median overall survival of 30 months in the VERSATILE-002 trial compares favorably to the 12.3 months reported for pembrolizumab in the KEYNOTE-048 trial for recurrent/metastatic head and neck cancer.
• The triple combination therapy (Versamune HPV + PDS01ADC + ICI) has shown a median overall survival of 42 months in a Phase 2 trial, which is significantly higher than the 17.9 months reported in the LEAP-010 trial for similar cancers.
• The objective response rate of 34% in the VERSATILE-002 trial is higher than the 11-17% reported for pembrolizumab in similar cancer types.
• The triple combination therapy has shown a 75% objective response rate, which is significantly higher than the 11-25% reported for pembrolizumab in similar cancer types.
• These results suggest that PDS Biotech's therapies may offer a significant improvement over existing treatments.

Stakeholder Impact

• Shareholders may view the positive clinical trial results favorably, potentially increasing the company's stock value.
• Patients with head and neck cancer may benefit from the potential new treatment options.
• Employees may be motivated by the progress of the company's clinical programs.
• The company's success could lead to increased business for suppliers and partners.

Next Steps

• The company plans to initiate a pivotal clinical trial in 2024 for its lead program in advanced head and neck squamous cell cancers.
• Full data from the May 17, 2024 data cut are expected to be announced in Q3 2024.
• The company anticipates an FDA meeting in July 2024 regarding the VERSATILE-003 protocol design.
• The company plans to file an IND for a Versamune MUC1 triple combination Phase 1/2 study in r/m colorectal cancer in Q4 2024.
• The company plans to provide a clinical update on the IMMUNOCERV trial in Q4 2024.

Key Dates

Keywords

PDS Biotechnology, VERSATILE-002, head and neck cancer, immunotherapy, Versamune HPV, pembrolizumab, PDS01ADC, clinical trial, median overall survival, HNSCC, HPV16, antibody-drug conjugate, T-cells